MS stands for multiple sclerosis, a chronic immune-mediated disease of the central nervous system that damages myelin and disrupts neural signaling. It can cause relapsing or progressive neurological disability.
FDA cleared Quantum Biopharma's IND for a Phase 2 trial of Lucid-MS in MS. Biogen's BIIB091 Phase 2 trial reached completion, and Bial concluded its ACTIVATE Phase IIb treatment period for GBA-PD.
CAR-T therapy reaches 150 patients in Ireland and expands into autoimmune trials for lupus and MS. Kyverna's miv-cel nears FDA approval for stiff person syndrome, and new research links gene variants to CAR-T outcomes.
Two new studies clarify how Epstein-Barr virus may trigger multiple sclerosis: one shows a doubled CD4+ T cell response in untreated patients, while another reveals EBV-activated B cells cause brain inflammation in mice. Insights point to potential therapies targeting EBV-specific immune activity.
AI-powered drugmaker Earendil Labs secured $787 million to advance biologics for autoimmune diseases and cancer, while Immunic locked in up to $400 million to fund Phase 3 trials of its multiple sclerosis therapy.
Immunic Inc presented additional data from its Phase 2 CALIPER trial at the ACTRIMS Forum, showing Vidofludimus calcium reduced both acute and chronic brain lesions in progressive multiple sclerosis patients and demonstrated clinical evidence of reduced EBV reactivation.
A Phase 1 trial of azer-cel, a CAR T-cell therapy using donor T-cells to target B-cells, is recruiting patients with progressive multiple sclerosis at eight U.S. sites. Separately, multiple randomized trials are comparing hematopoietic stem cell transplantation against high-efficacy disease-modifying therapies.
Over 10 companies are developing 12+ pipeline therapies for Neuromyelitis Optica Spectrum Disorder, including Roche's satralizumab Phase III pediatric trial and multiple anti-CD20 monoclonal antibody candidates.
NeuraLight will present a neuroprogression biomarker that outperforms the current gold standard for tracking Parkinson's disease progression at the AD/PD 2026 conference in Copenhagen beginning March 17.
Phase III FENtrepid trial results show investigational BTK inhibitor fenebrutinib met its primary endpoint of non-inferiority to ocrelizumab in primary progressive MS, with a 12% reduction in disability progression risk and strongest effect on upper limb function.
BioNxt Solutions Inc. receives European Patent No. 4539857 for its proprietary sublingual cladribine oral thin film drug delivery technology, providing protection across up to 39 European Patent Convention states through at least June 14, 2043.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07222618 |
"Selfie" Videos: A Novel, Patient-centered, Comprehensive Approach to Measuring Function in MS |
RECRUITING | |
| NCT06775912 |
Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases |
RECRUITING | EARLY_PHASE1 |
| NCT06548620 |
A Study of RD06-04 in Patients With Active Autoimmune Diseases |
WITHDRAWN | EARLY_PHASE1 |
| NCT06384976 |
KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT06143930 |
Blood Flow Restriction Training in Multiple Sclerosis |
RECRUITING | NA |
| NCT05865405 |
A Closed Loop, Doctor to Patient, Mobile Application for Depression in People With Multiple Sclerosis |
ACTIVE_NOT_RECRUITING | NA |
| NCT05102682 |
Robotics for Mobility Rehabilitation in MS |
COMPLETED | PHASE1 |
| NCT04415372 |
Macromolecular Imaging of White and Gray Matter Pathology in Multiple Sclerosis |
ENROLLING_BY_INVITATION | |
| NCT04148313 |
A Pilot Study to Explore the Role of Gut Flora in Multiple Sclerosis |
WITHDRAWN | |
| NCT03316404 |
Evaluating Multiple Sclerosis Patients ShOWing A GEnomic Signature of Therapy Response |
COMPLETED |
